IRMA-International.org: Creator of Knowledge
Information Resources Management Association
Advancing the Concepts & Practices of Information Resources Management in Modern Organizations

Cancer Immunotherapy: Beyond Checkpoint Inhibitors

Cancer Immunotherapy: Beyond Checkpoint Inhibitors
View Sample PDF
Author(s): Mohammad Raghibul Hasan (College of Applied Medical Sciences, Shaqra University, Al-Quwayiyah, Saudi Arabia), Bader Saud Alotaibi (College of Applied Medical Sciences, Shaqra University, Al-Quwayiyah, Saudi Arabia), Sultan F. Alnomasy (College of Applied Medical Sciences, Shaqra University, Al-Quwayiyah, Saudi Arabia) and Khalid Umar Fakhri (Department of Biosciences, Jamia Millia Islamia, New Delhi, India)
Copyright: 2021
Pages: 41
Source title: Handbook of Research on Advancements in Cancer Therapeutics
Source Author(s)/Editor(s): Sumit Kumar (National Institute of Pathology, New Delhi, India), Moshahid Alam Rizvi (Jamia Millia Islamia, India) and Saurabh Verma (National Institute of Pathology, India)
DOI: 10.4018/978-1-7998-6530-8.ch001

Purchase

View Cancer Immunotherapy: Beyond Checkpoint Inhibitors on the publisher's website for pricing and purchasing information.

Abstract

Cancer immunotherapy has become a powerful clinical strategy as well as an established pillar for the treatment of cancers to improving the prognosis of many cancer patients with a broad variety of solid tumors as well as blood cancers. The primary goals of immunotherapy are (a) to increase anti-tumor response, (b) decrease the immune suppression, and (c) to enhance the immunogenicity of tumors. This chapter aims to discuss the mechanism and different types of immunotherapies used for different cancers. It will also focus on recombinant products including immunostimulants, immunotoxins, antibodies, fusion proteins, engineered cytotoxic T cells, engineered immunocytokines, vaccines, checkpoint inhibitors, CAR T-cell therapy, and nanomedicine. Although immunotherapy has a rare side effect, it is not fully understood. The development of new strategies has been on the clinical trial to enhance the benefit of cancer patients to meet with challenges of limited efficacy and/or toxicity.

Related Content

Mayuree Tangkiatkumjai. © 2022. 12 pages.
Dawn-Marie Walker, Mayuree Tangkiatkumjai. © 2022. 13 pages.
G. Ramadhas, A.S. Suman Sankar, N.V. Sugathan. © 2022. 17 pages.
Aashaq Hussain Bhat, Himani Goyal Sharma. © 2022. 19 pages.
Kiran Mustafa, Javaria Kanwal, Sara Musaddiq, Samia Khakwani. © 2022. 14 pages.
Sreekumari Kurissery, Leah Katherine Shaw, Nandakumar Kanavillil. © 2022. 25 pages.
Ankita Gautam. © 2022. 18 pages.
Body Bottom